clinical trial · NCT07203755
Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine
CanSino Biologics Inc.·phase1·recruiting·n = 260
Diphtheria, Tetanus and Acellular PertussisEpidemic MeningitisHaemophilus Influenzae Type B InfectionAdsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4)DTcP-Hib-MCV4DTcP-Hib-MCV4DTcP-Hib-MCV4DTcP-Hib-MCV4Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis (DTcP)Haemophilus influenzae type b (Conjugate) (Hib)Meningococcal Group ACYW135 (Conjugate) (MCV4)
brief summary
This clinical trial is conducted in two parts. Part One employs a randomized, partially blinded, dose-escalation, partially active-controlled design. Part Two utilizes a randomized, blinded, placebo-controlled design. Part One is divided into four stages based on age and vaccine dose levels. Part Two consists of the 2-month-old vaccine/placebo groups.
started
Dec 19, 2025
primary completion
Feb 1, 2029
completion
Feb 1, 2029
last updated
Dec 31, 2025
official title
A Randomized, Partially Blinded, Dose-Exploratory, Active/Placebo-Controlled Phase I Clinical Trial Evaluating the Safety and Immunogenicity of the Adsorbed Acellular Pertussis (Tricomponent) DPT-Hib (Conjugate)-ACYW135-Group B Meningococcal (Conjugate) Combined Vaccine in Individuals Aged 2 Months to 6 Years
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol